Risk of Ovarian Cancer in a BRCA1 Mutation Carrier


  • Cumulative lifetime risk of ovarian cancer:
    • In a BRCA1 mutation carrier by age 70:
      • Is 40% to 59%
  • Risk reducing salpingooforectomy (RRSO) is recommended at:
      • Completion of childbearing or by age 35 to 40 years:
      • These will reduce the risks of:
        • Ovarian cancer by 80%
        • Breast cancer by 50%
  • BRCA2 mutation carriers:
    • Should be counseled regarding the possibility of recessive inheritance of a Fanconi anemia / brain tumor syndrome in their children:
      • If both partners carry a BRCA2 mutation
  • Annual surveillance of BRCA carriers with:
    • Transvaginal pelvic ultrasound and CA 125:
      • Has not been proven effective in reducing risk of death from ovarian cancer
      • Has no impact on the risk of developing ovarian cancer:
        • However, National Comprehensive Cancer Network guidelines:
          • Still recommend these tests every 6 months:
            • Until recommended RRSO is performed in this high-risk patient population
  • Use of oral contraceptives:
    • Has been shown to be effective in reducing ovarian cancer risk in BRCA mutation carriers:
      • By 43% in a meta-analysis with no significant increase in breast cancer risk in case-control studies



  1. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-1333.
  2. Cibula D, Zikan M, Dusek L, et al. Oral contraceptives and risk of ovarian and breast cancer in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther. 2011;11:1197-1207.
  3. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491-7496.
  4. Mavaddat N, Peock S, Frost D, et al; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105:812-822.
  5. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. V.2.2016. Available (with login) at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed June 25, 2016.
  6. Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst. 2003;95:1548-1551.
  7. Woodward ER, Sleightholme HV, Considine AM, et al. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007;114:1500-1509.
  • Rodrigo Arrangoiz MS, MD, FACS cirujano oncology y cirujano de mamá de Sociedad Quirúrgica S.C en el America British Cowdray Medical Center en la ciudad de Mexico:
    • Es experto en el manejo del cáncer de mama.
This image has an empty alt attribute; its file name is 20d943b1-6f20-49c3-9754-2f3756051c93-e1549581617191.jpg

👉Es miembro de la American Society of Breast Surgeons:

This image has an empty alt attribute; its file name is img_4130-1.jpg


• General surgery:

• Michigan State University:

• 2004 al 2010

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• Fox Chase Cancer Center (Filadelfia):

• 2010 al 2012

• Masters in Science (Clinical research for health professionals):

• Drexel University (Filadelfia):

• 2010 al 2012

• Surgical Oncology / Head and Neck Surgery / Endocrine Surgery:

• IFHNOS / Memorial Sloan Kettering Cancer Center:

• 2014 al 2016

This image has an empty alt attribute; its file name is image-42.jpg










Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s